OncologyEducation.com’s Best of ASCO® Conference is a program licensed by the American Society of Clinical Oncology and will be held on June 20, 2017 in Montréal, Québec. The focus of this event will be to provide medical oncologists and other healthcare practitioners with a summary of the most significant treatment advances presented at the ASCO 2017 Annual Meeting, with presentations focused on several key disease sites.
1. To summarize the most significant treatment advances presented at ASCO 2017.
2. To review the current standard of care for key malignancies.
3. To discuss the current controversies in the management of specific cancers.
Medical oncologists, pharmacists, nurses, and other oncology healthcare professionals.
Early bird rates - Deadline: Sunday May 21st
Physician Rate - $129.00
Nurses & Allied Health - $65.00
Physician Rate - $179.00
Nurses & Allied Health - $95.00
Dr. Jamil Asselah, MD
Dr. Asselah is a Medical Oncologist trained in Algiers and Paris, obtaining his MD from Algiers University of Medicine. He joined McGill University in 2011 as Assistant Professor in the Department of Oncology. He is now Director of the Predoctoral Medical Education in Oncology.
Dr. Asselah has been the principal investigator in numerous clinical research protocols, and has been part of several research groups at the Provincial and National level. His research interests include Breast Cancers, Gastrointestinal Cancers, and Cancers of the Head and Neck.
Dr. Michel Pavic, MD
Dr. Pavic is a Medical Oncologist at Centre intégré universitaire de santé et de services sociaux de l'Estrie – Centre Hospitalier Universitaire de Sherbrooke and an assistant professor of the Faculty of Medicine and Health Sciences of the Université de Sherbrooke. He is also the Chief of the Hemato-Oncology department at Hôpital Fleurimont, CIUSS de l’Estrie –CHUS. Dr. Pavic is the lead for numerous courses and training programs in his native France.
His clinical activities focus on hematological, urological, gastrointestinal, and breast cancers and he has participated in several clinical research protocols in venous thrombosis, immunodeficiencies, prostate cancer, and kidney cancer.
*This meeting has been approved by the American Society of Clinical Oncology. ASCO is not the CME provider for this activity.
**Best of ASCO® and any related logos are trademarks of the American Society of Clinical Oncology®.